At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
VKTX Viking Therapeutics
Market Closed 04-26 16:00:00 EDT
74.31
+5.45
+7.91%
盘后74.40
+0.09+0.12%
19:59 EDT
High74.64
Low68.22
Vol3.54M
Open69.00
D1 Closing68.86
Amplitude9.32%
Mkt Cap8.19B
Tradable Cap7.75B
Total Shares110.23M
T/O251.99M
T/O Rate3.39%
Tradable Shares104.25M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Viking Therapeutics, Inc. (NASDAQ:VKTX) Q1 2024 Earnings Call Transcript
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.